



FILE COPY

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: S. W. Fesik, *et al.*

Group Art Unit: 1642

Serial No.: 09/716,395

Certificate of Facsimile Transmission under 37 CFR §1.8(a):

Filed: November 20, 2000

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via facsimile, said transmission to be completed before midnight Eastern time on the date shown below, addressed to the following recipient:

For: MUTANT BCL-2 PROTEINS AND USES THEREOF

Assistant Commissioner for Patents  
Attn: Examiner Brenda G. Brumback  
Group Art Unit 1642  
Washington, D.C. 20231

Attorney Docket No.: 6752.US.O1

Date: March 28, 2002

Examiner: B. Brumback

Recipient Telefax Number: (703)-872-9306

*Kimberly A. Iofin* 03/28/02  
Kimberly A. Iofin Date

RESPONSE TO RESTRICTION REQUIREMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

RECEIVED

DEC 27 2002

Dear Sir:

Please amend the above-identified application as indicated below.

TECH CENTER 1600/2900

IN THE CLAIMS

Please CANCEL claims 15-18, WITHOUT PREJUDICE.

Remarks

This communication is in response to the Office Action, mailed March 11, 2002 in the above identified patent application. Claims 1-18 currently are pending. In the Office Action, the Examiner restricted Applicants' invention to one of two designated groups, namely, Group I (claims 1-14, drawn to a mutant human Bcl-2 protein) and Group II (claims 15-18, drawn to a method for identifying substances which bind to a Bcl-2 protein). Applicants hereby elect the invention of Group I, without traverse. Applicants reserve the right to file a divisional application directed to the nonelected subject matter.



23492

ABBOTT LABORATORIES  
Telephone: (847) 938-3137  
Facsimile: (847) 938-2623

Respectfully submitted,  
S. W. Fesik, *et al.*

*Dianne Casuto*  
Dianne Casuto  
Registration No. 40,943  
Attorney for Applicants